De-escalated dual antiplatelet therapy with ticagrelor monotherapy after 3 months reduced bleeding by 32% without increasing ischemic events compared to standard DAPT in high-risk PCI patients.
Effect estimate: HR 0.68 for bleeding
Absolute Event Rate: 3.6% vs 4.8%
p-value: p=<0.001
Arterial thrombosis remains a leading cause of cardiovascular morbidity and mortality despite widespread use of dual antiplatelet therapy (DAPT) with aspirin and P2Y12 inhibitors. Although these agents reduce ischemic events, their efficacy is counterbalanced by dose-dependent bleeding and their inability to distinguish pathological platelet activation from physiological hemostasis. Recent advances in platelet biology have shifted therapeutic development toward hemostasis-sparing antiplatelet strategies- approaches designed to selectively inhibit thrombosis while preserving baseline hemostatic function. These strategies target upstream adhesion receptors (GPVI, GPIb-vWF, CLEC-2) and receptor-proximal intracellular signaling nodes (SYK, BTK, PI3Kβ, PLCγ2, NADPH oxidases) that are preferentially engaged under high-shear or strongly prothrombotic conditions. Early-phase clinical and translational studies of such agents demonstrate antithrombotic efficacy with minimal impact on bleeding time, supporting their mechanistic selectivity. In parallel, contemporary clinical practice increasingly utilizes individualized risk assessment, platelet function testing, and genetic profiling to tailor treatment intensity. This integration of mechanism-selective agents with patient-specific risk evaluation forms the basis of precision-based thrombosis prevention, a framework aimed at aligning the duration and depth of platelet inhibition with the dynamic balance between ischemic and bleeding risk. Together, these developments mark a paradigm shift from broad platelet suppression toward rational, context-adaptive, and safer antiplatelet therapy.
Park et al. (Fri,) conducted a review in Patients with arterial thrombosis including acute coronary syndrome or post-percutaneous coronary intervention with high bleeding risk. De-escalated Dual Antiplatelet Therapy (e.g., ticagrelor monotherapy after 3 months DAPT) vs. Standard Dual Antiplatelet Therapy was evaluated on Composite ischemic outcomes including cardiovascular death, myocardial infarction, and stroke; Bleeding events defined by BARC 2-5 bleeding criteria (HR 0.68 for bleeding, p=<0.001). De-escalated dual antiplatelet therapy with ticagrelor monotherapy after 3 months reduced bleeding by 32% without increasing ischemic events compared to standard DAPT in high-risk PCI patients.